Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Malespin v. Longeveron Inc. et al
Case Number:
1:21-cv-23303
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
October 16, 2023
Biotech Investors Get Final Nod For $1.4M Settlement
Biotechnology company Longeveron Inc. and its investors on Monday saw a Miami federal judge give a final nod to a $1.4 million settlement agreement that ends claims the company overhyped the prospects for a drug it was developing as it was going public.
-
May 01, 2023
Biotech Investor Makes 2nd Push For $1.4M Deal Approval
A proposed class of investors in biotechnology company Longeveron Inc. has renewed its bid for an initial green light for a nearly $1.4 million settlement deal with the company after a federal judge in Miami earlier rejected their proposed plaintiffs' service award and requested revisions to their plans to formally request an attorney fee.
-
February 08, 2022
Rosen Law Firm Nabs Lead In Biotech Investor's Drug Row
The Rosen Law Firm PA will represent a proposed class of investors in biotechnology company Longeveron Inc. in a suit accusing the company of overstating the prospects for a therapeutic product the company was testing as it made $24.7 million off of an initial public offering.
-
September 14, 2021
Fla. Biotech Co.'s Misleading IPO Hurt Investors, Suit Says
A biotechnology company cofounded by one of South Florida's most prominent real estate developers has been hit with a proposed securities class action claiming the company made false and misleading statements about a key product in the months leading up to and following its February initial stock offering.